Keytruda (pembrolizumab) 100 mg injection is an immunotherapy medication used to treat a variety of cancers by helping the body's immune system fight cancer cells. It is administered by a healthcare professional as an intravenous (IV) infusion, typically over 30 minutes.
Key Information
Active Ingredient: Pembrolizumab, a monoclonal antibody.
Function: Keytruda is a PD-1 inhibitor (immune checkpoint inhibitor). It works by blocking the PD-1 receptor on immune T-cells, which prevents cancer cells from using this pathway to hide from the immune system, thus allowing the T-cells to recognize and attack the cancer.
Administration: It is given as an IV infusion in a hospital or clinic setting, usually every 3 or 6 weeks, depending on the specific cancer and treatment plan. A newer subcutaneous (under the skin) injection form (Keytruda Qlex) is also available in some regions, which takes less time to administer.
Uses: It is approved for use either alone or in combination with other therapies (like chemotherapy or radiation) for numerous cancers, including:
Melanoma (skin cancer)
Non-small cell lung cancer (NSCLC)
Head and neck squamous cell carcinoma (HNSCC)
Classical Hodgkin lymphoma
Urothelial cancer (bladder and urinary tract cancer)
Triple-negative breast cancer (TNBC)
Colorectal, gastric, cervical, kidney, and endometrial cancers, especially those with specific biomarkers (like PD-L1 positive or MSI-H/dMMR status)
Boost your visibility and reach more customers by listing your business with us. It's quick, easy, and absolutely free! Join thousands of businesses benefiting from our platform.
Add My Business arrow_forwardCopyright © 2026 Plumint.